---
title: "CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295790594.md"
description: "Advanced clinical programs in WM and TNBC, with strong efficacy data and a robust cash position of $34M as of June 30, 2026. NDA for iopofosine I 131 in WM planned for mid-2027, supported by recent financing and positive trial results.Original document: Cellectar Biosciences, Inc. [CLRB] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T11:28:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295790594.md)
  - [en](https://longbridge.com/en/news/295790594.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295790594.md)
generator: "portal-rs"
---

# CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM

Advanced clinical programs in WM and TNBC, with strong efficacy data and a robust cash position of $34M as of June 30, 2026. NDA for iopofosine I 131 in WM planned for mid-2027, supported by recent financing and positive trial results.

Original document: Cellectar Biosciences, Inc. \[CLRB\] SEC 8-K Current Report — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)

## Related News & Research

- [CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials](https://longbridge.com/en/news/296262059.md)
- [Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296502875.md)
- [14:30 ETMavrix defiende la importancia de la evidencia humana confiable en la era de la IA en el evento de Quirk](https://longbridge.com/en/news/296136546.md)
- [Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program](https://longbridge.com/en/news/296262041.md)
- [Memory: Everyone Puked The Lows. Now They're Chasing The Highs](https://longbridge.com/en/news/296139862.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**